ARCHIVES

Oblimersen Combination Improves CLL Survival

This article is from The Cancer Letter archive.

Vol. 30 No. 12 | December 28, 2007

Download PDF Visit The Full Archive

Related Articles

340B Drug Discount Program: HRSA Defends Orphan Drug Rule

June 20, 2014

Funding Opportunities

February 28, 2003

Two Phase II Trials Display Ramucirumab Potential Efficacy

October 26, 2012

ODAC Advice Poses Challenge to FDA: Would Iressa Approval Erode Standards?

November 8, 2002

CDC Study Finds No Correlation Between Alcohol, Breast Cancer

April 8, 1988

NCAB Considering Concept Review Of Large, Expensive Investigator Initiated Proposals

February 16, 1990